


## 1-Deoxynojirimycin

<b>Cat. No.:</b>	HY-14860		
<b>CAS No.:</b>	19130-96-2		
<b>Molecular Formula:</b>	C <sub>6</sub> H <sub>13</sub> NO <sub>4</sub>		
<b>Molecular Weight:</b>	163.17		
<b>Target:</b>	Glycosidase; PI3K		
<b>Pathway:</b>	Metabolic Enzyme/Protease; PI3K/Akt/mTOR		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : ≥ 34 mg/mL (208.37 mM)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	6.1286 mL	30.6429 mL	61.2858 mL
	5 mM	1.2257 mL	6.1286 mL	12.2572 mL
	10 mM	0.6129 mL	3.0643 mL	6.1286 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

1. Add each solvent one by one: PBS  
 Solubility: 100 mg/mL (612.86 mM); Clear solution; Need ultrasonic

### BIOLOGICAL ACTIVITY

#### Description

1-Deoxynojirimycin (Duvoglustat) is a potent and orally active  $\alpha$ -glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features<sup>[1][2]</sup>.

#### In Vivo

1-Deoxynojirimycin (Duvoglustat) (20-80 mg/kg; i.v.; daily for four weeks) shows anti-obesity effect<sup>[3]</sup>. 1-Deoxynojirimycin significantly improves insulin sensitivity via activating insulin signaling PI3K/AKT pathway in skeletal muscle of db/db mice<sup>[3]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	db/db mice <sup>[3]</sup>
---------------	---------------------------

Dosage:	20, 40, 80 mg/kg
Administration:	Intravenously; daily for four weeks
Result:	Significantly reduced body weight, blood glucose and serum insulin levels; Improved glucose tolerance and insulin tolerance.

## CUSTOMER VALIDATION

- Adv Healthc Mater. 2025 Jan 7:e2404015.
- Environ Microbiol. 2021 Mar 15.
- J Biol Chem. 2023 Sep 1;105211.
- Exp Cell Res. 2020 Nov 2;397(1):112334.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Chaluntorn Vichasilp, et al. Development of high 1-deoxynojirimycin (DNJ) content mulberry tea and use of response surface methodology to optimize tea-making conditions for highest DNJ extraction. LWT - Food Science and Technology. Volume 45, Issue 2, March 2012, Pages 226-232
- [2]. Gao K, et al. 1-Deoxynojirimycin: Occurrence, Extraction, Chemistry, Oral Pharmacokinetics, Biological Activities and In Silico Target Fishing. Molecules. 2016 Nov 23;21(11). pii: E1600.
- [3]. Liu Q, et al. 1-Deoxynojirimycin Alleviates Insulin Resistance via Activation of Insulin Signaling PI3K/AKT Pathway in Skeletal Muscle of db/db Mice. Molecules. 2015 Dec 4;20(12):21700-14.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA